Nov 14, 2023 / 02:45PM GMT
Paul Andrew Matteis - Stifel, Nicolaus & Company, Incorporated, Research Division - Co-Head of the Biotech Team, MD & Senior Analyst
All right. Thanks, everybody. Super happy to be here doing a panel with 2 executives from Alnylam, Pushkal Garg, Chief Medical Officer; and Jeff Poulton, Chief Financial Officer.
I'm going to have maybe each of these guys just kind of quickly chime in and give a quick snapshot of Alnylam on the pipeline side and then the financial side briefly, and then we will get into, as Pushkal said, the root canal on HELIOS-B. So let's do it. Thank you.
Pushkal P. Garg - Alnylam Pharmaceuticals, Inc. - Chief Medical Officer and Executive VP of Development & Medical Affairs
Well, Paul, thanks for having us here today. Really excited to be here with you and the team. Look, I think Alnylam was founded 22 years ago or so. And we couldn't be prouder of the progress we've made. We've basically developed a whole new class of medicines with 5 marketed products that are treating thousands and thousands of patients around the world.
Alnylam Pharmaceuticals Inc at Stifel Healthcare Conference Transcript
Feb 06, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers